Please login to the form below

Not currently logged in

Akcea Therapeutics

This page shows the latest Akcea Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Novartis highlights emerging assets and late-stage pipeline at R&D day

Novartis highlights emerging assets and late-stage pipeline at R&D day

TQJ230, an antisense oligonucleotide it licensed from Akcea Therapeutics in February, which reduces Lp(a), a currently untreatable risk factor for cardiovascular disease – an outcomes trial of over 7, 500 patients

Latest news

More from news
Approximately 2 fully matching, plus 6 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs


Add my company
The Good Ideas Group

Remarkable but responsible creative work. We're most passionate about the pursuit of original, powerful ideas that our clients can harness...

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....